to investigate efficacy and safety of a single injection of org 36286 for ovarian stimulation using daily recombinant fsh as reference (ensure)(p05690/mk-8962-001)

Conditions: Infertility

Summary: clinical trial objectives are to investigate the efficacy and safety of a single injection of 100 μg org 36286 in women weighing 60 kg or less to induce multifollicular development for controlled ovarian stimulation (cos), using daily recfsh as a reference.

this is a randomized, double-blind, active-controlled, equivalence clinical trial investigating the efficacy and safety of a new treatment regimen with org 36286, a recombinant gonadotropin applied to initiate and sustain follicular stimulation in cos for assisted reproductive technology (art). for this regimen, patients receive a single injection of org 36286 and one week later, treatment is continued with daily recfsh up to the day of triggering final oocyte maturation. in the reference group patients receive daily injections of recfsh up to the day of triggering final oocyte maturation. equivalence between the two treatment groups in the number of oocytes retrieved is the primary objective of this trial.

Eligibility criteria:
inclusion criteria: * females of couples with an indication for cos and ivf or icsi; * \>=18 and \<= 36 years of age at the time of signing informed consent; * body weight \ = 18 and \<= 32 kg/m\^2; * normal menstrual cycle length: 24-35 days; * availability of ejaculatory sperm (use of donated and/or cryopreserved sperm is allowed); * willing and able to sign informed consent. exclusion criteria: * history of/or any current (treated) endocrine abnormality; * history of ovarian hyper-response or ovarian hyperstimulation syndrome (ohss); * history of/or current polycystic ovary syndrome (pcos); * more than 20 basal antral follicles \<11 mm (both ovaries combined) as measured on uss in the early follicular phase (menstrual cycle day 2-5); * less than 2 ovaries or any other ovarian abnormality (including endometrioma \> 10 mm; visible on uss); * presence of unilateral or bilateral hydrosalphinx (visible on uss); * presence of any clinically relevant pathology affecting the uterine cavity or fibroids \>= 5 cm; * more than three unsuccessful ivf cycles since the last established ongoing pregnancy (if applicable); * history of non- or low ovarian response to fsh/hmg treatment; * history of recurrent miscarriage (3 or more, even when unexplained); * fsh \> 12 iu/l or lh \> 12 iu/l as measured by the local laboratory (sample taken during the early follicular phase: menstrual cycle day 2-5); * any clinically relevant abnormal laboratory value based on a sample taken during the screening phase; * contraindications for the use of gonadotropins (e.g. tumors, pregnancy/lactation, undiagnosed vaginal bleeding, hypersensitivity, ovarian cysts); * recent history of/or current epilepsy, hiv infection, diabetes, cardiovascular, gastro-intestinal, hepatic, renal or pulmonary disease; * abnormal karyotyping of the patient or her partner (if karyotyping is performed); * smoking more than 5 cigarettes per day; * history or presence of alcohol or drug abuse within 12 months prior to signing informed consent; * previous use of org 36286; * use of hormonal preparations within 1 month prior to randomization; * hypersensitivity to any of the concomitant medication prescribed as part of the treatment regimen in this protocol; * administration of investigational drugs within three months prior to signing informed consent.

Keywords: in vitro fertilization pharmacological effects of drugs hormones hormone substitutes and hormone antagonists pharmacological actions randomized multi-center multi-national double-blind active-controlled equivalence